explore -WSS

explore

author：leisure time 2025-09-06 09:10:24 - browse：1381

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： TikTok, Instagram influencers need more rules for drug ads

WSS

Medicare drug price lawsuits could be good politics for Biden

FDA needs staff influx to meet gene therapy needs, Marks says

Cardiologists urge adding sexual orientation, gender identity to health records

Inaction leaves children at risk from dangerous chemotherapy drug

CMS should re

STAT letters to the editor on burnt

knowledge

explore

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Prior authorization reform is both possible and imperative

Dobbs anniversary: the lost opportunity of abortion as health care

The woman behind the Dana Farber

DIEP, the 'gold standard' of breast reconstruction, is under threat

There's an unseen cost to disruptive road

New air purifier tech could be key to improving indoor air quality

Pregnancy discrimination could be enabled by AI

Medicare proposal to cover medical devices draws a mixed reaction

Spinal cord stimulation reduces pain in amputees, study finds

explore

Why sickle cell disease is getting the first CRISPR treatment

To bolster infectious disease surveillance, genomics powerhouses team up

There's an unseen cost to disruptive road

In diabetes hearing, Sanders takes on a new foe: food makers

Why sickle cell disease is getting the first CRISPR treatment

FDA approves world's first CRISPR

leisure time

explore

focus

leisure time